10-Q · May 11, 2026
MAIA's latest 10-Q reveals a substantial net loss of $6.37 million for Q1 2026, 41% higher than the previous year. Operating expenses rose sharply, primarily due to increased general and administrative costs, reflecting…
Earnings analysis · 10-Q
MAIA earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or current-period EPS, so revenue, margins, EPS, cash flow, and year-over-year trends cannot be…
Read full summary
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or current-period EPS, so revenue, margins, EPS, cash flow, and year-over-year trends cannot be quantified from the available filing text. The principal update is material litigation exposure: Wainwright seeks $2,310,616.88 in cash and warrants for 1,540,411 shares at $1.875 per share. MAIA also issued 16,724 shares in total for services across June 9 and July 7, 2026 with no cash proceeds, while providing no numeric outlook.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
-
No material control changes
The company reported no changes in internal control over financial reporting during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, such controls.
-
Service-provider equity issuance disclosed
MAIA issued 8,362 shares valued at $14,550 on June 9, 2026 and another 8,362 shares valued at $14,550 on July 7, 2026 for services, with no cash proceeds received.
What to watch
-
Material underwriting litigation exposure
H.C. Wainwright seeks $2,310,616.88 in cash plus warrants to purchase 1,540,411 shares at an exercise price of $1.875 per share in litigation related to the March 2026 offering. MAIA filed a motion to dismiss on June 26, 2026, but stated it cannot predict the outcome.
-
Noncash equity issuance and dilution
The company issued 8,362 shares valued at $14,550 on June 9, 2026 and 8,362 shares valued at $14,550 on July 7, 2026 in exchange for services, receiving no cash proceeds, indicating potential ongoing reliance on equity-based settlement or compensation.
-
Legal costs and resource diversion
The filing states that proceedings or claims can cause defense and settlement costs and diversion of resources; the Wainwright complaint was filed on April 22, 2026 and remains at an early stage.
Management's outlook
The supplied 10-Q extract provides no quantitative revenue or EPS outlook. No new numeric guidance is disclosed; the filing states that no additional risk factors were added beyond the December 31, 2025 Form 10-K.
Earlier filings 4
10-K · March 23, 2026
MAIA Biotechnology is a clinical-stage biotech focused on ateganosine, a telomere‑targeting immunotherapy being developed for advanced NSCLC and other solid tumors. The company reports promising Phase 2 efficacy (e.g.,…
10-Q · August 11, 2025
MAIA reported a Q2 2025 net loss of $(5,346,963) (EPS $(0.18)), an improvement from Q2 2024 net loss of $(8,879,276) (EPS $(0.40)). Cash increased to $10,144,522 as of June 30, 2025 (up $543,224 from $9,601,298 at…
10-K · March 21, 2025
MAIA is a clinical-stage biotech focused on THIO, a telomere-targeting immunotherapy. Phase 2 THIO-101 data show encouraging efficacy signals (e.g., 38% ORR in an efficacy-evaluable subset and median OS of 16.9 months…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.